Asimov

Today we are announcing a strategic collaboration with @LonzaGroup to advance in vivo lentiviral vector manufacturing.

In vivo lentiviral therapies turn the vector from a manufacturing reagent into the drug itself, raising the bar for titer, product quality, and scale. While traditional transient production systems limit scalability and consistency, stable cell lines have the potential to enable scalable, reproducible and controlled product profiles for lentiviral vectors.

To provide developers with a scalable path from sequence to clinic, we’re bringing together Asimov’s LV Edge stable cell lines with Lonza’s expertise in process development, scale-up, analytics and GMP manufacturing. By connecting early design decisions with development and manufacturing considerations, we are creating a stronger foundation for clinical and commercial production.

Learn more here: asimov.com/news/lonza-and…

Welcome back @AsimovPress!

Announcing our project with the Biomedical Advanced Research and Development Authority (BARDA) to improve manufacturing of antibody therapeutics for Ebola and other deadly viruses.

This three-year project aims to optimize production of a monoclonal antibody cocktail targeting filovirus disease caused by Ebola virus or Sudan virus, which are associated with mortality rates as high as 90 percent. Asimov will use its CHO Edge system to amplify the production of mAbs against these pathogens, ultimately enabling greater availability of these treatments.

Our AI-driven cell line and bioprocess design tools consistently deliver 8–11 g/L titers for IgGs and complex multispecifics.

Join us tomorrow to learn how we use predictive modeling, rather than trial-and-error, to optimize biologics production: hubs.li/Q03pQVxM0

We're parterning with Cytiva to help customers optimize biologics production, from mAbs to multispecifics.

We’ve spent years refining our CHO Edge platform in Cytiva’s HyClone media and feed, and now routinely achieve 7-11 g/L clones across biologic modalities...